Skip to Main Content

Noffar Bar, MD

Assistant Professor of Medicine (Hematology)

Contact Information

Noffar Bar, MD

Mailing Address

  • Hematology

    PO Box 208028

    New Haven, CT 06520-8028

    United States

Research Summary

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma.

Extensive Research Description

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar's research interests focus on improving the care of patients with multiple myeloma and other plasma cell dyscrasias.

Coauthors

Selected Publications

Clinical Trials

ConditionsStudy Title
LungAn Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer
Multiple MyelomaA Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Non-Hodgkin's LymphomaA Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Multiple MyelomaA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis
Multiple MyelomaNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Multiple MyelomaEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
KidneyA Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Multiple MyelomaA Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Multiple MyelomaA Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release